Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: OSA, Heart Failure, Myocardial Infarction, Arrhythmia, Cardiac
Interventions: Continuous Positive Airway Pressure; Device
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fontana, California

Conditions: Multiple Sclerosis, Neuropathic Pain
Interventions: glibenclamide, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Wellness
Interventions: Wellness Intention; Other
Lead sponsor: Merraki Institute; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: COVID-19, SAR-CoV-2
Interventions: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195), 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Healthy Volunteers
Interventions: TAK-828, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cachexia
Interventions: GSK2849466, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Interventions: BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: Healthy
Interventions: HU6 450 mg Tablet, HU6 150 mg Capsules x 3 (Total dose = 450 mg); Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Tirabrutinib, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 9
States / cities: Sacramento, California • Miami, Florida • Orlando, Florida + 6 more

Conditions: Solid Cancer
Interventions: R-DXd, Paclitaxel, Topotecan, PLD; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 45
States / cities: Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 33 more

Conditions: Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis
Interventions: Azeliragon, CSI; Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
Interventions: Resistant Potato Starch, Maltodextrin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Primary Ciliary Dyskinesia
Interventions: VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Bemcentinib, Pembrolizumab, Pemetrexed, Carboplatin; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Interventions: HY209GEL Active, Placebo; Drug · Other
Lead sponsor: Shaperon; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 4 more

Conditions: Chronic HBV Infection
Interventions: EDP-514, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 11
States / cities: Coronado, California • Los Angeles, California • San Diego, California + 8 more

Conditions: Smoking
Interventions: Saliva sample, Urine Sample, Toe nail clippings, Breath carbon monoxide test; Other
Lead sponsor: University of Florida; Other
Eligibility: 6 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Gainesville, Florida • Oklahoma City, Oklahoma

Conditions: Crohn's Disease
Interventions: Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR); Drug
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 11
States / cities: Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more

Conditions: Head and Neck Surgery
Interventions: REVEAL 475 System, Bevonescein; Device · Drug
Lead sponsor: Alume Biosciences, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Gallbladder Adenocarcinoma
Interventions: HIPEC; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer, Atypical Mesothelial Proliferation, Colorectal Cancer
Interventions: Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin, Doxorubicin, Hyperthermic Intraperitonial Chemotherapy, Cisplatin, Mitomycin C; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Phenylketonuria
Interventions: JNT-517 Suspension, Placebo Suspension, JNT-517 Tablet, Placebo Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Cardiovascular Disease
Interventions: AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: CSL312; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Anaheim, California

Search by objective public record fields.

Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized Cardiac Patients

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

Consciousness Field Project: Intention Host Device-mediated Distant Intentionality

Long-term Effects of COVID-19

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Relative Bioavailability Study of HU6

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Concurrent Azeliragon With Craniospinal Irradiation

A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Comparison of Smoking and Vaping in Families

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults